Publication: 3794

Publication: 3794

Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202

URL

Google Scholar

Citation:: Clinical Lymphoma, Myeloma & Leukemia vol 22 (Supplement 1) P-282

Meeting Instance:: IMS 2022
Year:: 2022
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3494 4250

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Celegene, Millennium-Takeda
Grants:: U10CA180821, U10CA180882

Corr. Author:
Authors:: Peter Voorhees Vera Suman Yvonne Efebera Noopur Raje Sascha Tuchman Cesar Rodriguez Katelyn Santo Misty Bova-Solem Destin Carlisle Saad Usmani Phil McCarthy Paul Richardson

Networks:: LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-NY158, NC002, NY021, OH008

Study: Alliance-A061202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 1/2

Keywords: